These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11902060)

  • 21. Should the medicare ESRD program pay for daily dialysis? An ethical analysis.
    Anantharaman P; Moss AH
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):290-6. PubMed ID: 17603984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
    Sahin S; Sahin GM; Ergin H; Kantarci G
    Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating traditional iron measures and exploring new options for patients on hemodialysis.
    Petroff S
    Nephrol Nurs J; 2005; 32(1):65-73; quiz 74-5. PubMed ID: 15787086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
    Bhandari S; Naudeer S
    J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Patients in pre-dialysis: decision taking and free choice of treatment].
    Sarrias Lorenz X; Bardón Otero E; Vila Paz ML
    Nefrologia; 2008; 28 Suppl 3():119-22. PubMed ID: 19018749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
    Silverberg DS; Wexler D; Iaina A
    J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of oral iron in the management of long-term hemodialysis patients.
    Lenga I; Lok C; Marticorena R; Hunter J; Dacouris N; Goldstein M
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):688-93. PubMed ID: 17699483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of dialysis therapies.
    Klarenbach S; Manns B
    Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supervised intradialytic oral iron administration during erythropoietin therapy.
    Fourtounas C; Koutsikos D; Dalamangas A; Kapetanaki A; Kostoglou M; Agroyannis B; Tzanatos H; Kopelias I; Bosiolis B
    Nephrol Dial Transplant; 1996 Jul; 11(7):1485-6. PubMed ID: 8815424
    [No Abstract]   [Full Text] [Related]  

  • 36. Changes and alternatives for dialysis facilities under the bundled payment plan.
    Solid CA; Collins AJ
    Nephrol News Issues; 2013 May; 27(6):30-2. PubMed ID: 23729081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of iron deficiency in chronic dialysis patients.
    van Zyl-Smit R
    Curr Opin Nephrol Hypertens; 2000 Nov; 9(6):669-74. PubMed ID: 11128430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comment on diagnosis and treatment of iron deficiency without anemia].
    Marko P
    Praxis (Bern 1994); 2010 Feb; 99(3):148; author reply 148. PubMed ID: 20127632
    [No Abstract]   [Full Text] [Related]  

  • 39. Do oral iron supplements have any role in dialysis patients?
    Mariani LH; Berns JS
    Semin Dial; 2011; 24(4):385-7. PubMed ID: 21801222
    [No Abstract]   [Full Text] [Related]  

  • 40. Comment to Sunder-Plassmann and Hörl.
    Shaldon S
    Clin Nephrol; 1997 Jun; 47(6):408. PubMed ID: 9202875
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.